WO2001032655A3 - Quinoline and naphthyridine carboxylic acid antibacterials - Google Patents

Quinoline and naphthyridine carboxylic acid antibacterials Download PDF

Info

Publication number
WO2001032655A3
WO2001032655A3 PCT/US2000/030551 US0030551W WO0132655A3 WO 2001032655 A3 WO2001032655 A3 WO 2001032655A3 US 0030551 W US0030551 W US 0030551W WO 0132655 A3 WO0132655 A3 WO 0132655A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinoline
carboxylic acid
naphthyridine carboxylic
antibacterials
acid antibacterials
Prior art date
Application number
PCT/US2000/030551
Other languages
French (fr)
Other versions
WO2001032655A2 (en
Inventor
Steven W Elmore
Curt S Cooper
Colleen C Schultz
Douglas K Hutchinson
Pamela L Donner
Brian E Green
David D Anderson
Qinghua Xie
Jurgen Dinges
Linda M Lynch
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to MXPA02004474A priority Critical patent/MXPA02004474A/en
Priority to BR0010728-0A priority patent/BR0010728A/en
Priority to EP00976992A priority patent/EP1226146A2/en
Priority to IL14873800A priority patent/IL148738A0/en
Priority to AU14689/01A priority patent/AU1468901A/en
Priority to JP2001535357A priority patent/JP2003524633A/en
Publication of WO2001032655A2 publication Critical patent/WO2001032655A2/en
Publication of WO2001032655A3 publication Critical patent/WO2001032655A3/en
Priority to NO20022156A priority patent/NO20022156L/en
Priority to BG106679A priority patent/BG106679A/en
Priority to HK02109077.5A priority patent/HK1047287A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Compounds having formula (I), or pharmaceutically acceptable salts or prodrugs thereof, wherein A1 is nitrogen or (II), wherein W is selected from the group consisting of (1) hydrogen and (2) optionally substituted alkyl; A2 is selected from the group consisting of (1) -S-, (2) -O-, and (3) -N(R7)-, wherein R7 is hydrogen or C¿1?-C6 alkyl; and R?5 and R6¿ together are a carbocyclic or a heterocyclic ring, are useful as antibacterial agents.
PCT/US2000/030551 1999-11-05 2000-11-06 Quinoline and naphthyridine carboxylic acid antibacterials WO2001032655A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA02004474A MXPA02004474A (en) 1999-11-05 2000-11-06 Quinoline and naphthyridine carboxylic acid antibacterials.
BR0010728-0A BR0010728A (en) 1999-11-05 2000-11-06 Antibacterial agents of quinoline and naphthyridine carboxylic acid
EP00976992A EP1226146A2 (en) 1999-11-05 2000-11-06 Quinoline and naphthyridine carboxylic acid antibacterials
IL14873800A IL148738A0 (en) 1999-11-05 2000-11-06 Quinoline and naphthyridine carboxylic acid antibacterials
AU14689/01A AU1468901A (en) 1999-11-05 2000-11-06 Quinoline and naphthyridine carboxylic acid antibacterials
JP2001535357A JP2003524633A (en) 1999-11-05 2000-11-06 Quinoline and naphthyridine carboxylic acid antibacterial agents
NO20022156A NO20022156L (en) 1999-11-05 2002-05-06 Quinoline and naphthyridinecarboxylic acid antibacterial agents
BG106679A BG106679A (en) 1999-11-05 2002-05-09 Quinoline and naphthyridine carboxylic acid antibacterials
HK02109077.5A HK1047287A1 (en) 1999-11-05 2002-12-13 Quinoline and naphthyridine carboxylic acid antibacterials

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43529799A 1999-11-05 1999-11-05
US09/435,297 1999-11-05
US70533200A 2000-11-03 2000-11-03
US09/705,332 2000-11-03

Publications (2)

Publication Number Publication Date
WO2001032655A2 WO2001032655A2 (en) 2001-05-10
WO2001032655A3 true WO2001032655A3 (en) 2002-01-24

Family

ID=27030507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030551 WO2001032655A2 (en) 1999-11-05 2000-11-06 Quinoline and naphthyridine carboxylic acid antibacterials

Country Status (12)

Country Link
EP (1) EP1226146A2 (en)
JP (1) JP2003524633A (en)
AR (1) AR030537A1 (en)
AU (1) AU1468901A (en)
BG (1) BG106679A (en)
BR (1) BR0010728A (en)
CZ (1) CZ20021531A3 (en)
HK (1) HK1047287A1 (en)
IL (1) IL148738A0 (en)
MX (1) MXPA02004474A (en)
NO (1) NO20022156L (en)
WO (1) WO2001032655A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018345A1 (en) * 2000-08-29 2002-03-07 Chiron Corporation Quinoline antibacterial compounds and methods of use thereof
CN1307875C (en) 2001-04-27 2007-04-04 宝洁公司 Compounds, compositions, and methods for controlling biofilms
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
WO2004083207A1 (en) * 2003-03-12 2004-09-30 Abbott Laboratories Naphthyridine derivatives as antibacterial agents
EP1829869A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
US20080139574A1 (en) 2006-11-30 2008-06-12 Cadila Healthcare Limited Novel quinoline derivatives
TWI498115B (en) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd Imidazole carbonyl compounds
AU2010325925B2 (en) 2009-12-04 2016-02-25 Pgi Drug Discovery Llc. Multicyclic compounds and methods of use thereof
JP2019523279A (en) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Compounds and compositions and their use
MA45857A (en) 2016-07-29 2021-05-19 Sunovion Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS, AND ASSOCIATED USES
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sunovion Pharmaceuticials Inc. Methods of treating schizophrenia
CA3070993A1 (en) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
KR20200122345A (en) 2018-02-16 2020-10-27 선오비온 파마슈티컬스 인코포레이티드 Salts, crystalline forms and methods for their preparation
MX2021010880A (en) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof.
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153163A2 (en) * 1984-02-17 1985-08-28 Warner-Lambert Company 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153163A2 (en) * 1984-02-17 1985-08-28 Warner-Lambert Company 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CURTS S. COOPER ET AL.: "The synthesis and antibacterial activities of quinolones containing five- and six-membered heterocyclic substituents at the 7-position", JOURNAL OF MEDICINAL CHEMISTRY., vol. 33, no. 3, - 1990, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 1246 - 1252, XP002169851, ISSN: 0022-2623 *
MIGUEL F. BRAÑA ET AL.: "Synthesis of benzimidazo-substituted 3-quinolinecarboxylic acids as antibacterial agents", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 27, no. 5, - 1990, HETEROCORPORATION. PROVO., US, pages 1177 - 1180, XP002169849, ISSN: 0022-152X *
SADAO NISHIGAKI ET AL.: "Synthetic antibacterials. V. 7-Substituted 1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids", CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 23, no. 12, - 1975, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO., JP, pages 3170 - 3177, XP002169850, ISSN: 0009-2363 *
THOMAS O. RICHARDSON ET AL.: "Synthesis of 7-Benzoxazol-2-yl and 7-Benzthiazol-2-yl-6-fluoro-quinolones", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 35, no. 5, - 1998, HETEROCORPORATION. PROVO., US, pages 1301 - 1304, XP002169848, ISSN: 0022-152X *

Also Published As

Publication number Publication date
MXPA02004474A (en) 2002-11-07
BR0010728A (en) 2004-02-17
AR030537A1 (en) 2003-08-27
JP2003524633A (en) 2003-08-19
NO20022156D0 (en) 2002-05-06
EP1226146A2 (en) 2002-07-31
NO20022156L (en) 2002-07-04
AU1468901A (en) 2001-05-14
IL148738A0 (en) 2002-09-12
WO2001032655A2 (en) 2001-05-10
CZ20021531A3 (en) 2002-09-11
HK1047287A1 (en) 2003-02-14
BG106679A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
WO2001032655A3 (en) Quinoline and naphthyridine carboxylic acid antibacterials
CA2205757A1 (en) Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
AU695045B2 (en) Heteroaromatic oxazole compounds and use thereof
WO2002024635A3 (en) Aminoalcohol derivatives
EP1103552A4 (en) Benzothiepin derivatives, process for the preparation of the same and uses thereof
GB0007405D0 (en) Compounds
WO2002032872A8 (en) Nitrogenous aromatic ring compounds
CA2206754A1 (en) Benzimidazole derivatives with antihistaminic activity
CA2290709A1 (en) 2,6-diaminopyridine compounds as intermediates for producing antibacterial dihydropyridone carboxylic acid derivatives
EP0422596A3 (en) Tricyclic carbapenem compounds
EP0703222A4 (en) 3-aminoazepine compound and pharmaceutical use thereof
AP2001002309A0 (en) 1-amino triazolo[4,3-A] quinazoline-5-ones and/or-5-thiones inhibiting phosphodiesterase IV.
WO1999000373A8 (en) Benzimidazole derivatives
AU4497293A (en) Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
WO1998046589A3 (en) Indazole amide compounds as serotoninergic agents
AU4946185A (en) Quinolonecarboxylic acid derivatives
ES8704932A1 (en) Quinolonecarboxylic acid derivatives.
AU6220300A (en) Benzofurylpiperazine serotonin agonists
EP1026162A4 (en) Antirheumatic
EP0878196A4 (en) Kainic acid neuronotoxicity inhibitors and pyridothiazine derivatives
CA2256609A1 (en) 5-aroylpyrrol-2-ylmethylarene derivatives as inhibitors of prostaglandin g/h synthase
MXPA02002355A (en) Process for production of naphthyridine 3 carboxylic acid derivatives.
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
AU5296199A (en) Antibacterial agents
WO2003024913A1 (en) SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148738

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 517934

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00394/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 14689/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000976992

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2002-1531

Country of ref document: CZ

Ref document number: 008153035

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2001 535357

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6192002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/004474

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 106679

Country of ref document: BG

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000976992

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-1531

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000976992

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2002-1531

Country of ref document: CZ